Abstract 81P
Background
Limited infiltration and exhaustion of transferred T cells are key factors impeding the development of adoptive cell immunotherapy in solid tumors. Efficient infiltration of activated T cells into tumors plays an important role in the therapeutic effect of adoptive cell immunotherapy. A tumor-penetrating peptide iRGD modified T cells (SmarT cells) were established to promote tumor-specific lymphocyte infiltration and enhanced the antitumor efficacy of PD-1 blocking strategy.
Methods
Here we report the interim analysis results of an ongoing phase 1/2 dose-escalation clinical trial of SmarT plus PD-1 mAb in patients with previously treated solid cancers (ChiCTR2200061306). The primary objective was safety for the combination of SmarT cells, low dose radiation and PD-1 mAb; secondary objectives included efficacy and dose-finding of SmarT cells.
Results
We treated 10 patients with three SmarT doses: 1.0 × 109, 5.0 × 109 or 10 × 109 cells. The low dose radiation (1Gy) was carried out 24 hours before SmarT injection. Three patients experienced a grade 2 fever. Two patients experienced a grade anemia. No cytokine release syndrome (CRS) occurred. No grade 3 or higher treatment-related adverse events or deaths were reported. A total of three patients had stable disease (SD) and seven patients had a progressive disease (PD). The disease control rate (DCR) reached 30.0%. The median progressive free survival time (mPFS) was 71 days and the median overall survival time (mOS) was 201 days.
Conclusions
These initial results suggest that SmarT cells has promising efficacy with an acceptable safety profile in patients with heavily pretreated solid cancers.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The legal committee of Nanjing Drumtower Hospital.
Funding
The funds for Clinical Trials from the Affiliated Drum Tower Hospital, Medical School of Nanjing University (No. 2022-LCYJ-ZD-05, B.L.).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
204P - A radiomics strategy based on CT intra-tumoral and peritumoral regions for preoperative prediction of neoadjuvant chemoradiotherapy for esophageal cancer
Presenter: zhiyang li
Session: Poster Display
Resources:
Abstract
205TiP - IMPACT: Randomized, multicenter, phase III study evaluating the efficacy of immunotherapy (atezolizumab) plus anti-VEGF therapy (bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma (HCC)
Presenter: Tatsuya Yamashita
Session: Poster Display
Resources:
Abstract
206TiP - SIERRA: A phase IIIb, single-arm, multicentre study of tremelimumab plus durvalumab for first-line treatment of advanced unresectable hepatocellular carcinoma
Presenter: Stephen Chan
Session: Poster Display
Resources:
Abstract
207TiP - A two-arm randomized open-label prospective design superiority phase III clinical trial to compare the efficacy of docetaxel-oxaliplatin-capecitabine/ 5 -fluorouracil (DOC/F) followed by docetaxel versus CAPOX/mFOLFOX-7 in advanced gastric cancers
Presenter: Prabhat Bhargava
Session: Poster Display
Resources:
Abstract
212P - Mutational landscape and characteristics of ERBB2 in urothelial carcinoma
Presenter: Mingwei Li
Session: Poster Display
Resources:
Abstract
213P - Prognostic significance of absolute lymphocyte count in patients with metastatic renal cell carcinoma treated with first-line combination immunotherapies: Results from the International metastatic renal cell carcinoma database consortium (IMDC)
Presenter: Kosuke Takemura
Session: Poster Display
Resources:
Abstract
214P - Development and prospective validation of a multiplex RNA urine test for noninvasive detection and surveillance of urothelial carcinoma
Presenter: Hua Xu
Session: Poster Display
Resources:
Abstract
215P - Real-world outcomes of first-line tislelizumab plus axitinib in patients with metastatic non-clear cell renal cell carcinoma (mnccRCC)
Presenter: Pei Dong
Session: Poster Display
Resources:
Abstract
216P - Preliminary efficacy and safety results from ‘ReBirth’: A phase II study of risk-based bladder-sparing therapy for MIBC
Presenter: Yijun Shen
Session: Poster Display
Resources:
Abstract
217P - Conditional reprogramming of urine-derived bladder cancer cells: A model for precision medicine
Presenter: Yu Dong
Session: Poster Display
Resources:
Abstract